Life Sciences Tools and Services
Company Overview of Cancer Research Institute, Inc.
Cancer Research Institute, Inc. engages in the support and coordination of scientific and clinical efforts that lead to the immunological treatment, control, and prevention of cancer. It specializes in immunology and cancer immunology research in the United States and internationally. The company provides cancer research programs, such as laboratory investigation and training programs, and clinical investigation programs; educational programs; public information programs; and conferences and meetings. It supports graduate students and postdoctoral fellows, as well as heads of university departments, hospitals, and clinics. Cancer Research Institute, Inc. was formerly known as New York Cancer...
One Exchange Plaza
New York, NY 10006
Founded in 1953
Key Executives for Cancer Research Institute, Inc.
Chief Executive Officer and Director of Scientific Affairs
President and Trustee Emeritus
Co-Founder and Trustee Emeritus
Chief Financial Officer and Director of Human Resources
Compensation as of Fiscal Year 2013.
Cancer Research Institute, Inc. Key Developments
CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer
Nov 4 13
Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. Amplifying the immune system's ability to recognize, attack, and destroy cancer, is a therapeutic strategy that recent studies have demonstrated to be a potent and effective approach to treatment of some cancers. Product approvals and promising clinical data for various checkpoint inhibitors, which block proteins responsible for immune system inhibition, support the potential of combining CureVac's RNActive(R) vaccines with this new class of treatment to significantly improve cancer patient survival. Ludwig and CRI will conduct up to five clinical studies of cancer immunotherapy combinations through their jointly coordinated CVC Trials Network using CureVac's investigational clinical stage drug, CV9202, combined with other priority agents available to CRI and Ludwig from their internal portfolios or accessed through additional industry partnerships. CV9202 contains NSCLC-associated antigens and is the optimized successor of CV9201, which has successfully completed a phase I/IIa clinical trial demonstrating its safety and immunogenicity. Additional investigational clinical stage drugs from CureVac's product pipeline can be added.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries